摘要:Pancreatic ductal adenocarcinoma (PDAC) is often perceived as an incurable disease by both patients and their physicians. While the outcome of most solid tumors has improved over the last 20 years, the median survival for patients with PDAC has steadily remained less than 12 months, even with the best therapeutic regimens currently available [1]. Despite the discouraging statistics, approximately 20% of all patients who undergo surgical resection for PDAC survive five years. Among these, a small percentage experience very long-term survival of more than ten years, and in some cases may even experience complete cure [2, 3].